• Hikma Pharmaceuticals discussed its H1 2026 interim results in a presentation attended by CEO Said Darwazah and Acting CFO Areb Kurdi.
• Core revenue rose 4%; core operating profit increased 9% to USD 405 million; core EBITDA grew 8% to USD 463 million; core EPS increased 5%.
• R&D spend increased 18%; Injectables sales and marketing investment rose about 10%, with further increases expected in H2.
• Branded revenue climbed 15% to USD 502 million; core operating profit rose 23% to USD 163 million; guidance shifted to top end of range.
• Net debt to core EBITDA ended at 1.9x; operating cash flow was USD 214 million; USD 39 million of capex tied to reimbursed CMO project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.